FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol

Schizophrenia Research

Volumn 94, Issue 1-3, 2007, Pages 293-305

  Buchsbaum, Monte S ^a   Haznedar, M Mehmet ^a   Aronowitz, Jonathan ^a   Brickman, Adam M ^a   Newmark, Randall E ^a   Bloom, Rachel ^a   Brand, Jesse ^a   Goldstein, Kim E ^a   Heath, Desmond ^a   Starson, Meghan ^a   Hazlett, Erin A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Early onset; Hypofrontality; Neuroleptic; Schizophrenia; Striatum; Thalamus

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HALOPERIDOL; OLANZAPINE;

ADOLESCENT; ADULT; ARTICLE; CALIFORNIA VERBAL LEARNING TEST; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG UPTAKE; FEMALE; FRONTAL LOBE; HUMAN; LEARNING; MALE; METABOLIC RATE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SERIAL VERBAL LEARNING TASK; TASK PERFORMANCE; THALAMUS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; COGNITION DISORDERS; FEMALE; FLUORODEOXYGLUCOSE F18; FRONTAL LOBE; HALOPERIDOL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; OCCIPITAL LOBE; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTIC DISORDERS; RADIOPHARMACEUTICALS; TEMPORAL LOBE;

EID: 34447098874     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.04.027     Document Type: Article

References (55)

1. Andreasen N., Flaum M., and Arndt S. The Comprehensive Assessment of Symptoms and History (CASH): An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 49 (1992) 615-623
2. Andreasen N.C., Rezai K., Alliger R., Swayze II V.W., Flaum M., Kirchner P., Cohen G., and O'Leary D.S. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch. Gen. Psychiatry 49 (1992) 943-958
3. Bartels P., and Subach J. Significance probability mappings and automated interpretation of complex pictorial scenes. In: Preston E., and Onoe M. (Eds). Digital Processing of Biomedical Imagery (1976), Academic Press, NY 101-114
4. Bartlett E.J., Wolkin A., Brodie J.D., Laska E.M., Wolf A.P., and Sanfilipo M. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry Res. Neuroimaging 40 (1991) 115-124
5. Berman I., Merson A., Sison C., Allan E., Schaefer C., Loberboym M., and Losonczy M.F. Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients: a pilot study. Psychopharmacol. Bull. 32 (1996) 95-100
6. Buchsbaum M.S., and Hazlett E.A. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr. Bull. 24 (1998) 343-364
7. Buchsbaum M.S., Hollander E., Pallanti S., Baldini Rossi N., Platholi J., Newmark R., Bloom R., and Sood E. Positron emission tomography imaging of Risperidone augmentation in SRI-refractory patients. Neuropsychobiology 53 (2006) 157-168
8. Buchsbaum M.S., Potkin S., Marshall J., Lottenberg S., Teng C.Y., Heh C.W., Tafalla R., Reynolds C., Abel L., Plon L., and Bunney W.E. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology 6 (1992) 155-163
9. Buchsbaum M.S., Potkin S.G., Siegel Jr. B.V., Lohr J., Katz M., Gottschalk L.A., Gulasekaram B., Marshall J.F., Lottenberg S., Teng C.Y., et al. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch. Gen. Psychiatry 49 (1992) 966-974
10. Buchsbaum M.S., Hazlett E.A., Haznedar M.M., Spiegel-Cohen J., and Wei T.C. Visualizing fronto-striatal circuitry and neuroleptic effects in schizophrenia. Acta Psychiatr. Scand., Suppl. 395 (1999) 129-137
11. Buchsbaum M.S., Hollander E., Haznedar M.M., Tang C., Spiegel-Cohen J., Wei T.C., Solimando A., Buchsbaum B.R., Robins D., Bienstock C., Cartwright C., and Mosovich S. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int. J. Neuropsychopharmacol. 4 (2001) 119-125
12. Buchsbaum M.S., Nenadic I., Hazlett E.A., Spiegel-Cohen J., Fleischman M.B., Akhavan A., Silverman J.M., and Siever L.J. Differential metabolic rates in prefrontal and temporal Brodmann areas in schizophrenia and schizotypal personality disorder. Schizophr. Res. 54 (2002) 141-150
13. Buchsbaum M.S., Christian B.T., Lehrer D.S., Narayanan T.K., Shi B., Mantil J., Kemether E., Oakes T.R., and Mukherjee J. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr. Res. 85 (2006) 232-244
14. Buchsbaum M.S., Hollander E., Pallanti S., Baldini Rossi N., Platholi J., Newmark R., Bloom R., and Sood E. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology 53 (2006) 157-168
15. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., and Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 (1996) 87-96
16. Cohen R.M., Nordahl T.E., Semple W.E., Andreason P., Litman R.E., and Pickar D. The brain metabolic patterns of clozapine-and fluphenazine-treated patients with schizophrenia during a continuous performance task. Arch. Gen. Psychiatry 54 (1997) 481-486
17. Delis D., Kramer J., Kaplan E., and Ober B. The California Verbal Learning Test (1987), Psychological Corporation, New York
18. Desco M., Gispert J.D., Reig S., Sanz J., Pascau J., Sarramea F., Benito C., Santos A., Palomo T., and Molina V. Cerebral metabolic patterns in chronic and recent-onset schizophrenia. Psychiatry Res. Neuroimaging 122 (2003) 125-135
19. Duncan G.E., Miyamoto S., Leipzig J.N., and Lieberman J.A. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J. Pharmacol. Exp. Ther. 293 (2000) 8-14
20. Duncan G.E., Miyamoto S., and Lieberman J.A. Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation. J. Pharmacol. Exp. Ther. 305 (2003) 999-1005
21. Fujimoto T., Takeuch K., Matsumoto T., Kamimura K., Hamada R., Nakamura K., and Kato N. Abnormal glucose metabolism in the anterior cingulate cortex in patients with schizophrenia. Psychiatry Res. Neuroimaging 154 (2007) 49-58
22. Hazlett E., Buchsbaum M., Mohs R., Spiegel-Cohen J., Wei T.C., Azueta R., Haznedar M., Singer M., Shihabuddin L., and Luu-Hisa C. Age-related shift in brain region allocation during successful memory performance. Neurobiol. Aging 19 (1998) 437-445
23. Hazlett E.A., Buchsbaum M.S., Haznedar M.M., Singer M.B., Schnur D.B., Jimenez E.A., Buchsbaum B.R., and Troyer B.T. Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology 35 (1998) 186-198
24. Hazlett E., Buchsbaum M., Byne W., Wei T.C., Spiegel-Cohen J., Geneve C., Kinderlehrer R., Haznedar M., Shihabuddin L., and Siever L. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am. J. Psychiatry 156 (1999) 1190-1199
25. Hendren R.L., De Backer I., and Pandina G.J. Review of neuroimaging studies of child and adolescent psychiatric disorders from the past 10 years. J. Am. Acad. Child Adolesc. Psych. 39 (2000) 815-828
26. Hirvonen J., van Erp T.G., Huttunen J., Nagren K., Huttunen M., Aalto S., Lonnqvist J., Kaprio J., Cannon T.D., Hia J., et al. Striatal dopamine D1 and D2 receptor balance in twins at increased genetic risk for schizophrenia. Psychiatry Res. Neuroimaging 146 (2006) 13-20
27. Holcomb H.H., Cascella N.G., Thaker G.K., Medoff D.R., Dannals R.F., and Tamminga C.A. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiatry 153 (1996) 41-49
28. Honey G.D., Bullmore E.T., Soni W., Varatheesan M., Williams S.C., and Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13432-13437
29. Ingvar D.H., and Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr. Scand. 50 (1974) 425-462
30. Jacobsen L.K., Hamburger S.D., Van Horn J.D., Vaituzis A.C., McKenna K., Frazier J.A., Gordon C.T., Lenane M.C., Rapoport J.L., and Zametkin A.J. Cerebral glucose metabolism in childhood onset schizophrenia. Psychiatry Res. Neuroimaging 75 (1997) 131-144
31. Lahti A.C., Holcomb H.H., Weiler M.A., Medoff D.R., and Tamminga C.A. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol. Psychiatry 53 (2003) 601-608
32. Lahti A.C., Weiler M.A., Medoff D.R., Tamminga C.A., and Holcomb H.H. Functional effects of single dose first-and second-generation antipsychotic administration in subjects with schizophrenia. Psychiatry Res. Neuroimaging 139 (2005) 19-30
33. Miller D.D., Andreasen N.C., O'Leary D.S., Watkins G.L., Boles Ponto L.L., and Hichwa R.D. Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol. Psychiatry 49 (2001) 704-715
34. Molina V., Gispert J.D., Reig S., Sanz J., Pascau J., Santos A., Palomo T., and Desco M. Cerebral metabolism and risperidone treatment in schizophrenia. Schizophr. Res. 60 (2003) 1-7
35. Molina V., Reig S., Pascau J., Sanz J., Sarramea F., Gispert J.D., Luque R., Benito C., Palomo T., and Desco M. Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia. Psychiatry Res. Neuroimaging 124 (2003) 163-175
36. Molina V., Gispert J.D., Reig S., Pascau J., Martinez R., Sanz J., Palomo T., and Desco M. Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia. Int. Clin. Psychopharmacol. 20 (2005) 13-18
37. Ngan E.T., Lane C.J., Ruth T.J., and Liddle P.F. Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change. J. Neurol. Neurosurg. Psychiatry 72 (2002) 106-110
38. Nordstrom A.L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., and Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry 33 (1993) 227-235
39. Oranje B., Kahn R.S., Kemner C., and Verbaten M.N. Modulating sensorimotor gating in healthy volunteers: the effects of desipramine and haloperidol. Psychiatry Res. 127 (2004) 195-205
40. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., Costa D., Perry R.H., and Perry E.K. Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine. Neuroscience 90 (1999) 433-445
41. Potkin S.G., Buchsbaum M.S., Jin Y., Tang C., Telford J., Friedman G., Lottenberg S., Najafi A., Gulasekaram B., Costa J., et al. Clozapine effects on glucose metabolic rate in striatum and frontal cortex. J. Clin. Psychiatry 55 Suppl B (1994) 63-66
42. Rosa-Neto P., Doudet D.J., and Cumming P. Gradients of dopamine D1-and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. NeuroImage 22 (2004) 1076-1083
43. Shenton M.E., Dickey C.C., Frumin M., and McCarley R.W. A review of MRI findings in schizophrenia. Schizophr. Res. 49 (2001) 1-52
44. Shihabuddin L., Buchsbaum M., Hazlett E., Haznedar M., Harvey P., Newman A., Schnur D., Spiegel-Cohen J., Wei T., Machac J., Knesaurek K., Vallabhojosula S., Biren M., Ciaravolo T., and Luu-Hsia C. Dorsal striatal size, shape, and metabolic rate in neuroleptic-naive and previously medicated schizophrenic patients performing a verbal learning task. Arch. Gen. Psychiatry 55 (1998) 235-243
45. Shihabuddin L., Buchsbaum M., Hazlett E., Silverman J., New A., Brickman A., Mitropoulou V., Nunn M., Fleischman M., Tang C., and Siever L. Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia. Arch. Gen. Psychiatry 58 (2001) 877-884
46. Simeon D., Guralnik O., Hazlett E.A., Spiegel-Cohen J., Hollander E., and Buchsbaum M.S. Feeling unreal: a PET study of depersonalization disorder. Am. J. Psychiatry 157 (2000) 1782-1788
47. StatSoft, I., 2003. Statistica. Tulsa, OK: www.statsoft.com.
48. Stein D.J., Buchsbaum M.S., Hof P.R., Siegel Jr. B.V., and Shihabuddin L. Greater metabolic rate decreases in hippocampal formation and proisocortex than in neocortex in Alzheimer's disease. Neuropsychobiology 37 (1998) 10-19
49. Talairach J., and Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain (1988), Thieme, Stuttgart
50. Talvik M., Nordstrom A.L., Olsson H., Halldin C., and Farde L. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int. J. Neuropsychopharmacol. 6 (2003) 361-370
51. Talvik M., Nordstrom A.L., Okubo Y., Olsson H., Borg J., Halldin C., and Farde L. Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res. Neuroimaging 148 (2006) 165-173
52. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Ding Y.S., Sedler M., Logan J., Franceschi D., Gatley J., Hitzemann R., Gifford A., Wong C., and Pappas N. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am. J. Psychiatry 158 (2001) 2015-2021
53. Woods R.P., Mazziotta J.C., and Cherry S.R. MRI-PET registration with automated algorithm. J. Comput. Assist. Tomogr. 17 (1993) 536-546
54. 3H] 2-deoxyglucose metabolic mapping. Schizophr. Res. 61 (2003) 195-205
55. 2 receptor binding in subregions of the thalamus in schizophrenia. Am. J. Psychiatry 161 (2004) 1016-1022